Patricia García-Fernández

Ms. Patricia García-Fernández

Department of Neurology, University Hospital Würzburg, Würzburg, Bavaria, Germany
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
PGPatricia García-Fernández
Patricia García-Fernández
KHKlemens Höfflin
Klemens Höfflin
ARAntonia Rausch
Antonia Rausch
KSKatharina Strommer
Katharina Strommer
ANAstrid Neumann
Astrid Neumann
CSClaudia Sommer
Claudia Sommer
Introduction: In patients with peripheral neuropathies (PNP), neuropathic pain is present in 50% of the cases, independent of the etiology. The pathophysiology of pain is poorly understood, and inflammatory processes have been found to be involved in neuro-degeneration, -regeneration and pain. While previous studies have found a local upregulation of inflammatory mediators in patients with PNP, there is a high variability described in the cytokines present systemically in sera and cerebrospinal fluid (CSF). We hypothesized that the development of PNP and neuropathic pain is associated with enhanced systemic inflammation.Methods: To test our hypothesis, we performed a comprehensive analysis of the protein, lipid and gene expression of different pro- and anti-inflammatory markers in blood and CSF from patients with PNP and controls.Results: While we found differences between PNP and controls in specific cytokines or lipids, such as CCL2 or oleoylcarnitine, PNP patients and controls did not present major differences in systemic inflammatory markers in general. IL-10 and CCL2 levels were related to measures of axonal damage and neuropathic pain. Lastly, we describe a strong interaction between inflammation and neurodegeneration at the nerve roots in a specific subgroup of PNP patients with blood-CSF barrier dysfunction.Conclusion: In patients with PNP systemic inflammatory, markers in blood or CSF do not differ from controls in general, but specific cytokines or lipids do. Our findings further highlight the importance of CSF analysis in patients with peripheral neuropathies.

1 January 2021 in Pain Reports
Verified
Journal Article
Open access
PGPatricia García-Fernández
Patricia García-Fernández
NÜNurcan Üçeyler
Nurcan Üçeyler
CSClaudia Sommer
Claudia Sommer
This review describes the roles of the low-density lipoprotein receptor–related protein 1 (LRP-1) in inflammatory pathways, nerve nerve degeneration and -regeneration and in neuropathic pain. Induction of LRP-1 is able to reduce the activation of the proinflammatory NFκB-mediated pathway and the mitogen-activated protein kinase (MAPK) c-Jun N-terminal kinase and p38 signaling pathways, in turn decreasing the production of inflammatory mediators. Low-density lipoprotein receptor-related protein 1 activation also decreases reactive astrogliosis and polarizes microglial cells and macrophages from a proinflammatory phenotype (M1) to an anti-inflammatory phenotype (M2), attenuating the neuroinflammatory environment. Low-density lipoprotein receptor-related protein 1 can also modulate the permeability of the blood–brain barrier and the blood–nerve barrier, thus regulating the infiltration of systemic insults and cells into the central and the peripheral nervous system, respectively. Furthermore, LRP-1 is involved in the maturation of oligodendrocytes and in the activation, migration, and repair phenotype of Schwann cells, therefore suggesting a major role in restoring the myelin sheaths upon injury. Low-density lipoprotein receptor-related protein 1 activation can indirectly decrease neurodegeneration and neuropathic pain by attenuation of the inflammatory environment. Moreover, LRP-1 agonists can directly promote neural cell survival and neurite sprouting, decrease cell death, and attenuate pain and neurological disorders by the inhibition of MAPK c-Jun N-terminal kinase and p38-pathway and activation of MAPK extracellular signal–regulated kinase pathway. In addition, activation of LRP-1 resulted in better outcomes for neuropathies such as Alzheimer disease, nerve injury, or diabetic peripheral neuropathy, attenuating neuropathic pain and improving cognitive functions. To summarize, LRP-1 plays an important role in the development of different experimental diseases of the nervous system, and it is emerging as a very interesting therapeutic target.

Verified
Journal Article
Open access
PDF file
PGPatricia García-Fernández
Patricia García-Fernández
CRColette Reinhold
Colette Reinhold
NÜNurcan Üçeyler
Nurcan Üçeyler
CSClaudia Sommer
Claudia Sommer
Polyneuropathy (PNP) is a term to describe diseases of the peripheral nervous system, 50% of which present with neuropathic pain. In some types of PNP, pain is restricted to the skin distally in the leg, suggesting a local regulatory process leading to pain. In this study, we proposed a pro-inflammatory pathway mediated by NF-κB that might be involved in the development of pain in patients with painful PNP. To test this hypothesis, we have collected nerve and skin samples from patients with different etiologies and levels of pain. We performed RT-qPCR to analyze the gene expression of the proposed inflammatory pathway components in sural nerve and in distal and proximal skin samples. In sural nerve, we showed a correlation of TLR4 and TNFα to neuropathic pain, and an upregulation of TNFα in patients with severe pain. Patients with an inflammatory PNP also presented a lower expression of TRPV1 and SIRT1. In distal skin, we found a reduced expression of TLR4 and miR-146-5p, in comparison to proximal skin. Our findings thus support our hypothesis of local inflammatory processes involved in pain in PNP, and further show disturbed anti-inflammatory pathways involving TRPV1 and SIRT1 in inflammatory PNP.

28 September 2026 in Communications Biology
Verified
Journal Article
Open access
PDF file
PGPatricia García-Fernández
Patricia García-Fernández
TBThorsten Bischler
Thorsten Bischler
ASAnnemarie Sodmann
Annemarie Sodmann
JGJulia Grüner
Julia Grüner
MKMaximilian Koch
Maximilian Koch
CSClaudia Sommer
Claudia Sommer
Polyneuropathies (PNP) are diseases of the peripheral nervous system (PNS) whose pathophysiology remains poorly understood. Schwann cells (SC) are the principle glial cells in the PNS, and their dysfunction can lead to demyelination and secondary axonal degeneration, causing or exacerbating PNP. The study of SC can thus shed light on the molecular and cellular mechanisms involved in PNP. Protocols have been developed to isolate and culture human and animal SC from large amounts of starting material. The isolation of human SC from patients, where only small biosamples are available, remains a challenge. In this study, we present a protocol to culture human SC from ~4-mm diagnostic sural nerve biopsies and a comprehensive transcriptome analysis to characterize their phenotype. Our protocol allows the reproducible establishment of cultures containing proliferative human Schwann cells that can be stored, expanded, and used as tools for diagnostic applications.